Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025年1月9日 - 8:30AM
ビジネスワイヤ（英語）
Incyte (Nasdaq:INCY) today announced that it granted restricted
stock unit awards (RSUs) representing an aggregate of 9,502 shares
of the Company’s common stock to 14 new employees. The awards were
made under the Company’s 2024 Inducement Stock Incentive Plan, with
a grant date and vesting commencement date of January 2, 2025, and
were approved by the compensation committee of the Company’s board
of directors as an inducement material to the new employees
entering into employment with the Company in accordance with Nasdaq
Listing Rule 5635(c)(4).
Each RSU vests as to 25% of the shares subject to the RSU on
each of the first four anniversaries of the vesting commencement
date, subject to the employee's continued service with the Company
on each such date.
About Incyte A global biopharmaceutical company on a
mission to Solve On., Incyte follows the science to find solutions
for patients with unmet medical needs. Through the discovery,
development and commercialization of proprietary therapeutics,
Incyte has established a portfolio of first-in-class medicines for
patients and a strong pipeline of products in Oncology and
Inflammation & Autoimmunity. Headquartered in Wilmington,
Delaware, Incyte has operations in North America, Europe and
Asia.
For additional information on Incyte, please visit Incyte.com or
follow us on social media: LinkedIn, X, Instagram, Facebook,
YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250108900343/en/
Media media@incyte.com
Investors ir@incyte.com
Incyte (NASDAQ:INCY)
過去 株価チャート
から 12 2024 まで 1 2025
Incyte (NASDAQ:INCY)
過去 株価チャート
から 1 2024 まで 1 2025
